Luteolin inhibits matrix metalloproteinase 9 and 2 in azoxymethane-induced colon carcinogenesis

Human and Experimental Toxicology

Volumn 33, Issue 11, 2014, Pages 1176-1185

  Pandurangan, A K ^a   Dharmalingam, P ^a   Sadagopan, S K A ^a   Ganapasam, S ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Azoxymethane; colon cancer; luteolin; MMP; TIMP 2

Indexed keywords

5' NUCLEOTIDASE; ACTIN; AZOXYMETHANE; CARCINOEMBRYONIC ANTIGEN; CATHEPSIN D; GAMMA GLUTAMYLTRANSFERASE; GELATINASE A; GELATINASE B; LUTEOLIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; ANTINEOPLASTIC AGENT; CARCINOGEN; MATRIX METALLOPROTEINASE INHIBITOR; MMP2 PROTEIN, MOUSE; MMP9 PROTEIN, MOUSE; TUMOR MARKER;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CELL DENSITY; COLON CARCINOGENESIS; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNOFLUORESCENCE; MALE; MAST CELL; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPPLEMENTATION; TUMOR VOLUME; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; COLON TUMOR; GENETICS; METABOLISM;

5'-NUCLEOTIDASE; ANIMALS; ANTINEOPLASTIC AGENTS; AZOXYMETHANE; CARCINOGENS; COLONIC NEOPLASMS; GAMMA-GLUTAMYLTRANSFERASE; LUTEOLIN; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MICE, INBRED BALB C; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84905996633     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327114522502     Document Type: Article

References (59)

1. Havsteen B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol. 1983 ; 32: 1141-1148
2. Wollenber E. Occurrence of flavonoid aglycones in medicinal plants. Prog Clin Biol Res. 1988 ; 280: 45-55
3. Vrijsen R, Everaert L, Boeye A. Antiviral activity of flavones and potentiation by ascorbate. J Gen Virol. 1988 ; 69: 1749-1751
4. Mittra B, Saha A, Chowdhury AR, et al. Luteolin, an abundant dietary component is a potent anti-leishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis. Mol Med. 2000 ; 6: 527-541
5. Yoshida M, Sakai T, Hosokawa N, et al. The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett. 1990 ; 260: 10-13
6. Perez-Garcia F, Adzet T, Canigueral S. Activity of artichoke leaf extract on reactive oxygen species in human leukocytes. Free Radic Res. 2000 ; 33: 661-665
7. Ashokkumar P, Sudhandiran G. Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomed Pharmacother. 2008 ; 62: 590-597
8. Pandurangan AK, Dharmalingam P, Anandasadagopan SK, et al. Effect of luteolin on the levels of glycoproteins during azoxymethane-induced colon carcinogenesis in mice. Asian Pac J Canc Prev. 2012 ; 13 (4). 1569-1573
9. Ashokkumar P, Sudhandiran G. Luteolin inhibits cell proliferation during azoxymethane-induced experimental colon carcinogenesis via Wnt/β-catenin pathway. Invest New Drugs. 2011 ; 29 (2). 273-284
10. Pandurangan AK, Dharmalingam P, Ananda Sadagopan SK, et al. Luteolin induces growth arrest in colon cancer cells through involvement of Wnt/β-catenin/GSK-3β signaling. J Environ Pathol Toxicol Oncol. 2013 ; 32 (2). 131-139
11. Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol. 1990 ; 1 (2). 99-106
12. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinses in metastasis. J Natl Canc Inst. 1997 ; 89 (17). 1260-1270
13. Riasu W. Mechanisms of angiogenesis. Nature. 1997 ; 386 (6626). 671-674
14. Folkman J, Shing Y. Angiogensis. J Biol Chem. 1992 ; 267: 10931-10934
15. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggests Flk-1 as a major regulator of vasculogenesis. Cell. 1993 ; 72: 835-846
16. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994 ; 79 (7). 1157-1164
17. Bergers G, Brekken R, Mahon GM, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000 ; 2: 737-744
18. Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA. 2000 ; 97: 4052-4057
19. Pepper MS. Extracellular proteolysis and angiogenesis. Throm Heamostasis. 2001 ; 86: 346-355
20. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol. 1996 ; 3 (11). 895-904
21. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999 ; 274 (31). 1491-1494
22. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002 ; 295 (5564). 2387-2392
23. Lin CW, Hou WC, Shen SC, et al. Quercetin inhibition of tumor invasion via suppressing PKC/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis. 2008 ; 29 (9). 1807-1815
24. Tahanian E, Sanchez LA, Shiao TC, et al. Flavonoids targeting of IB phosphorylation abrogates carcinogen-induced MMP-9 and COX-2 expression in human brain endothelial cells. Drug Des Dev Ther. 2011 ; 5: 299-309
25. Kim JH, Kim JH, Kim SC, et al. Adenosine dialdehyde suppresses MMP-9-mediated invasion of cancer cells by blocking the Ras/Raf-1/ERK/AP-1 signaling pathway. Biochem Pharmacol. 2013 ; 86 (9). 1285-1300
26. Zeng ZS, Huang Y, Cohen AM, et al. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol. 1996 ; 14: 3133-3140
27. Sriram N, Kalayrasan S, Ashokkumar P, et al. Diallyl sulfide induces apoptosis in Colo 320 DM human colon cancer cells: involvement of caspase-3, NF-B, and ERK. Mol Cell Biochem. 2008 ; 311: 157-165
28. Kumar A, Pandurangan AK, Lu F, et al. Chemopreventive sphingadienes downregulate wnt signaling via a PP2A/Akt/GSK3 pathway in colon cancer. Carcinogenesis. 2012 ; 33 (9). 1726-1735
29. Pandurangan AK, Ananda Sadagopan SK, Dharmalingam P, et al. Luteolin, a bioflavonoid inhibits azoxymethane-induced colorectal cancer through Nrf2 signaling. Toxicol Mech Methods. 2014 ; 24 (1). 13-20
30. Pandurangan AK, Ananda Sadagopan SK, Dharmalingam P, et al. Inhibitory effect of luteolin on azoxymethane-induced colon carcinogenesis: involvement of iNOS and COX-2. Pharmacog Magazine. 2013 ;:
31. Shafie NH, Esa NM, Ithnin H, et al. Prophylactic inositol hexaphosphate (IP6) inhibits colon cancer through involvement of Wnt/β-catenin and COX-2 pathway. BioMed Res Int. 2013 ;:
32. Fine E,, Ipta PL, Palmerini CA, et al. 5 -nucleotidase from bull plasma. Biochim Biophys Acta. 1983 ; 748: 405-412
33. Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. J Biol Chem. 1925 ; 66: 375-400
34. Rosalki SB, Ran D. Serum gamma glutamyl transpeptidase activity in alcoholism. Clin Chim Acta. 1972 ; 39: 41-47
35. Sapolsky AL, Altman RD, Howell DS. Cathepsin-D activity in normal and osteoarthritic human cartilage. Fed Proc. 1973 ; 32: 1489-1493
36. Sachdev GP, Wen G, Martin B, et al. Effects of dietary fat and alpha-tocopherol on gamma-glutamyltranspeptidase activity in 7, 12,-dimethyl benz(a)anthracene induced mammary gland adenocarcinomas. Canc Biochem Biophys. 1980 ; 5: 15-23
37. Ngo EO, Nutler LM. Status of glutathione and glutathione-metabolizing enzymes in menadione-resistant human cancer cells. Biochem Pharmacol. 1994 ; 47: 421-424
38. Ko Y, Klinz M, Totzke G, et al. Limitations of the reverse transcription-polymerase chain reaction method for the detection of carcinoembryonic antigen-positive tumor cells in peripheral blood. Clin Canc Res. 1998 ; 4: 141-146
39. Goeminne JC, Guillaume T, Symann M. Pitfalls in the detection of disseminated non-hematological tumor cells. Ann Oncol. 2000 ; 1 (7). 785-792
40. Ranieri G, Labriola A, Achille G, et al. Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma. Int J Oncol. 2002 ; 21 (6). 1317-1323
41. Iamaroon A, Pongsiriwet S, Jittidecharaks S, et al. Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma. J Oral Pathol Med. 2003 ; 32 (4). 195-199
42. Srinivasan P, Sabitha KE, Shyamaladevi CS. Modulatory efficacy of green tea polyphenols on glycoconjugates and immunological markers in 4-nitroquinoline 1-oxide-induced oral carcinogenesis: a therapeutic approach. Chem Biol Int. 2006 ; 162 (2). 149-156
43. Maeda-Yamamoto M, Kawahara H, Matsuda N, et al. Effects of tea infusions of various varieties or different manufacturing types on inhibition of mouse mast cell activation. Biosci Biotechnol Biochem. 1998 ; 62: 2277-2279
44. Theoharides TC, Kempuraj D, Iliopoulou BP. Mast cells, T cells, and inhibition by luteolin: implications for the pathogenesis and treatment of multiple sclerosis. Adv Exp Med Biol. 2007 ; 601: 423-430
45. Kimata M, Shichijo M, Miura T, et al. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy. 2000 ; 30 (4). 501-508
46. Kimata M, Inagaki N, Nagai H. Effects of luteolin and other flavonoids on IgE-mediated allergic reactions. Planta Med. 2000 ; 66 (1). 25-29
47. Whittaker M, Floyd CD, Brown P, et al. Design and the therapeutic application of matrix metalloproteinases inhibitors. Chem Rev. 1999 ; 99 (9). 2735-2776
48. Pandurangan AK. Potential targets for the prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Canc Prev. 2013 ; 14 (4). 2201-2205
49. Pandurangan AK, Esa NM. Dietary non-nutritive factors on molecular targets of colorectal cancer: an update. Asian Pac J Canc Prev. 2013 ; 14 (10). 5543-5552
50. Tseng CN, Huang CF, Cho CL, et al. Brefeldin A effectively inhibits cancer stem cell-like properties and MMP-9 activity in human colorectal cancer colo 205 cells. Molecules. 2013 ; 8 (9). 10242-10253
51. Pitchakarn P, Chewonarin T, Ogawa K, et al. Ellagic acid inhibits migration and invasion by prostate cancer cell lines. Asian Pac J Canc Prev. 2013 ; 14 (5). 2859-2863
52. Park SH, Kim JH, Lee DH, et al. Luteolin 8-C-β-fucopyranoside inhibits invasion and suppresses TPA-induced MMP-9 and IL-8 via ERK/AP-1 and ERK/NF-B signaling in MCF-7 breast cancer cells. Biochimie. 2013 ; 95 (11). 2082-2090
53. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003 ; 22: 6524-6536
54. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Canc. 2002 ; 99: 157-166
55. Sounni NE, Janssen M, Foidart JM, et al. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol. 2003 ; 22: 55-61
56. Hornebeck W, Emonard H, Monboisse JC, et al. Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin Canc Biol. 2002 ; 12: 231-241
57. Klein G, Vellenga E, Fraaije MW, et al. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol. 2004 ; 50: 87-100
58. Kinoshita T, Sato H, Okada A, et al. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem. 1998 ; 273: 16098-16103
59. Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A: a kinetic study. J Biol Chem. 1998 ; 273: 871-880